Qualcomm Unveils Dragonfly C1000 and Lands Multi-Generation Meta AI Deal
At Investor Day 2026, Qualcomm announced Dragonfly C1000 for AI workloads, major Meta partnership, Microsoft collaboration, and sharply raised long-term targets.
/ 220 items
#andre↓
Raymond James Highlights Viking’s New Amylin-Based Weight Loss Drug VK3019 Entering Clinic
Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.
Cantor Fitzgerald Initiates Overweight Coverage on Silence Therapeutics, Calls Stock “Materially Undervalued”
The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.
Absci Rockets on Positive ABS-201 Data and $100M Financing Backed by Eli Lilly
Eli Lilly participates in Absci’s $100M equity offering to fund ABS-201, a novel prolactin receptor antibody showing strong safety in Phase 1 for pattern hair loss and endometriosis.
BlackBerry Gets Buy Rating from Stifel at $12 as Analyst Highlights Physical AI Opportunity
Stifel launches Buy coverage on BlackBerry, arguing that the market underappreciates its evolving role in the physical AI ecosystem.
Cerebras Reports Strong Revenue Growth in First Post-IPO Earnings, Stock Falls on Margin Concerns
Despite reporting 94% revenue growth and securing a multi-year OpenAI agreement worth over $20 billion, Cerebras shares fell in after-hours trading on lower margin guidance.